GentiBio Announces $157M Series A Financing to Advance Engin

GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation

© 2025 Vimarsana